

LANDOS BIOPHARMA, INC.  
1800 Kraft Drive, Suite 216  
Blacksburg, VA 24060

Februaruy 1, 2021

VIA EDGAR

United States Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549  
Attn: Jenn Do  
Kevin Kuhar  
Christopher Edwards  
Alan Campbell

**RE: Landos Biopharma, Inc.  
Registration Statement on Form S-1  
File No. 333-252083**

**Acceleration Request**

**Requested Date: February 3, 2021  
Requested Time: 4:00 P.M. Eastern Time**

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “**Registrant**”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-1 (the “**Registration Statement**”) to become effective on February 3, 2021, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.

Once the Registration Statement has been declared effective, please orally confirm that event with Madison Jones, counsel to the Registrant, at (202) 728-7087.

Very truly yours,

**Landos Biopharma, Inc.**

/s/ Josep Bassaganya-Riera

\_\_\_\_\_  
Josep Bassaganya-Riera  
Chairman, President and Chief Executive Officer

cc: Eric Blanchard, Cooley LLP  
Madison Jones, Cooley LLP